engineering of phage-derived lytic enzymes: improving their potential as antimicrobials
Klicks: 301
ID: 187771
2018
Artikelqualität & Leistungskennzahlen
Gesamtqualität
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Leser-Engagement
Steady Performance
30.0
/100
301 Aufrufe
30 Leser
KI-Qualitätsbewertung
Nicht analysiert
Readership in this journal
SteadyRanked #10 of 25 articles by views in derecho pucp
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Lytic enzymes encoded by bacteriophages have been intensively explored as alternative agents for combating bacterial pathogens in different contexts. The antibacterial character of these enzymes (enzybiotics) results from their degrading activity towards peptidoglycan, an essential component of the bacterial cell wall. In fact, phage lytic products have the capacity to kill target bacteria when added exogenously in the form of recombinant proteins. However, there is also growing recognition that the natural bactericidal activity of these agents can, and sometimes needs to be, substantially improved through manipulation of their functional domains or by equipping them with new functions. In addition, often, native lytic proteins exhibit features that restrict their applicability as effective antibacterials, such as poor solubility or reduced stability. Here, I present an overview of the engineering approaches that can be followed not only to overcome these and other restrictions, but also to generate completely new antibacterial agents with significantly enhanced characteristics. As conventional antibiotics are running short, the remarkable progress in this field opens up the possibility of tailoring efficient enzybiotics to tackle the most menacing bacterial infections.
| Referenzschlüssel |
so-jos2018antibioticsengineering
Verwenden Sie diesen Schlüssel zum automatischen Zitieren im Manuskript bei Verwendung von
SciMatic Manuscript Manager oder Thesis Manager
|
|---|---|
| Autoren | ;Carlos São-José |
| Zeitschrift | derecho pucp |
| Jahr | 2018 |
| DOI |
10.3390/antibiotics7020029
|
| URL | |
| Schlüsselwörter |
Zitationen
Keine Zitationen gefunden. Um eine Zitation hinzuzufügen, kontaktieren Sie den Administrator unter info@scimatic.org
Kommentare
Noch keine Kommentare. Seien Sie der Erste, der diesen Artikel kommentiert.